Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43


Mucin-Like Domain of Ebola Virus Glycoprotein Enhances Selective Oncolytic Actions against Brain Tumors.

Zhang X, Zhang T, Davis JN, Marzi A, Marchese AM, Robek MD, van den Pol AN.

J Virol. 2020 Mar 31;94(8). pii: e01967-19. doi: 10.1128/JVI.01967-19. Print 2020 Mar 31.


Virus-like Vesicles Expressing Multiple Antigens for Immunotherapy of Chronic Hepatitis B.

Yarovinsky TO, Mason SW, Menon M, Krady MM, Haslip M, Madina BR, Ma X, Moshkani S, Chiale C, Pal AC, Almassian B, Rose JK, Robek MD, Nakaar V.

iScience. 2019 Nov 22;21:391-402. doi: 10.1016/j.isci.2019.10.040. Epub 2019 Oct 24.


Mechanisms of Innate Immune Activation by a Hybrid Alphavirus-Rhabdovirus Vaccine Platform.

Marchese AM, Chiale C, Moshkani S, Robek MD.

J Interferon Cytokine Res. 2020 Feb;40(2):92-105. doi: 10.1089/jir.2019.0123. Epub 2019 Oct 18.


Heterologous prime-boost immunization with vesiculovirus-based vectors expressing HBV Core antigen induces CD8+ T cell responses in naïve and persistently infected mice and protects from challenge.

Chiale C, Moshkani S, Rose JK, Robek MD.

Antiviral Res. 2019 Aug;168:156-167. doi: 10.1016/j.antiviral.2019.05.014. Epub 2019 May 30.


A Highly Attenuated Vesicular Stomatitis Virus-Based Vaccine Platform Controls Hepatitis B Virus Replication in Mouse Models of Hepatitis B.

Moshkani S, Chiale C, Lang SM, Rose JK, Robek MD.

J Virol. 2019 Feb 19;93(5). pii: e01586-18. doi: 10.1128/JVI.01586-18. Print 2019 Mar 1.


An ELISPOT-Based Assay to Measure HBV-Specific CD8+ T Cell Responses in Immunocompetent Mice.

Reynolds TD, Moshkani S, Robek MD.

Methods Mol Biol. 2017;1540:237-247.


Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection.

Reynolds TD, Buonocore L, Rose NF, Rose JK, Robek MD.

J Virol. 2015 Oct;89(20):10407-15. doi: 10.1128/JVI.01184-15. Epub 2015 Aug 5.


Cytidine deamination and cccDNA degradation: A new approach for curing HBV?

Ding S, Robek MD.

Hepatology. 2014 Dec;60(6):2118-21. doi: 10.1002/hep.27386. Epub 2014 Oct 29. No abstract available.


Peroxisomal MAVS activates IRF1-mediated IFN-λ production.

Ding S, Robek MD.

Nat Immunol. 2014 Aug;15(8):700-1. doi: 10.1038/ni.2924. No abstract available.


Type III interferon attenuates a vesicular stomatitis virus-based vaccine vector.

Guayasamin RC, Reynolds TD, Wei X, Fujiwara M, Robek MD.

J Virol. 2014 Sep;88(18):10909-17. doi: 10.1128/JVI.01910-14. Epub 2014 Jul 9.


Long-distance interferon signaling within the brain blocks virus spread.

van den Pol AN, Ding S, Robek MD.

J Virol. 2014 Apr;88(7):3695-704. doi: 10.1128/JVI.03509-13. Epub 2014 Jan 15.


Epigenetic reprogramming of the type III interferon response potentiates antiviral activity and suppresses tumor growth.

Ding S, Khoury-Hanold W, Iwasaki A, Robek MD.

PLoS Biol. 2014 Jan;12(1):e1001758. doi: 10.1371/journal.pbio.1001758. Epub 2014 Jan 7.


Functional characterization of the putative hepatitis B virus core protein late domain using retrovirus chimeras.

Garcia ML, Reynolds TD, Mothes W, Robek MD.

PLoS One. 2013 Aug 29;8(8):e72845. doi: 10.1371/journal.pone.0072845. eCollection 2013.


Dynamic expression profiling of type I and type III interferon-stimulated hepatocytes reveals a stable hierarchy of gene expression.

Bolen CR, Ding S, Robek MD, Kleinstein SH.

Hepatology. 2014 Apr;59(4):1262-72. doi: 10.1002/hep.26657. Epub 2014 Feb 18.


A vesicular stomatitis virus-based therapeutic vaccine generates a functional CD8 T cell response to hepatitis B virus in transgenic mice.

Cobleigh MA, Wei X, Robek MD.

J Virol. 2013 Mar;87(5):2969-73. doi: 10.1128/JVI.02111-12. Epub 2012 Dec 26.


Protective and pathological properties of IL-22 in liver disease: implications for viral hepatitis.

Cobleigh MA, Robek MD.

Am J Pathol. 2013 Jan;182(1):21-8. doi: 10.1016/j.ajpath.2012.08.043. Epub 2012 Nov 14. Review.


The blood transcriptional signature of chronic hepatitis C virus is consistent with an ongoing interferon-mediated antiviral response.

Bolen CR, Robek MD, Brodsky L, Schulz V, Lim JK, Taylor MW, Kleinstein SH.

J Interferon Cytokine Res. 2013 Jan;33(1):15-23. doi: 10.1089/jir.2012.0037. Epub 2012 Oct 15.


The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate.

Cobleigh MA, Bradfield C, Liu Y, Mehta A, Robek MD.

J Virol. 2012 Apr;86(8):4253-61. doi: 10.1128/JVI.05991-11. Epub 2012 Feb 15.


A proinflammatory role for interleukin-22 in the immune response to hepatitis B virus.

Zhang Y, Cobleigh MA, Lian JQ, Huang CX, Booth CJ, Bai XF, Robek MD.

Gastroenterology. 2011 Nov;141(5):1897-906. doi: 10.1053/j.gastro.2011.06.051. Epub 2011 Jun 25.


Interferon-λ in HCV Infection and Therapy.

Pagliaccetti NE, Robek MD.

Viruses. 2010 Aug;2(8):1589-602. doi: 10.3390/v2081589. Epub 2010 Aug 5.


Interferon-lambda in the immune response to hepatitis B virus and hepatitis C virus.

Pagliaccetti NE, Robek MD.

J Interferon Cytokine Res. 2010 Aug;30(8):585-90. doi: 10.1089/jir.2010.0060. Review.


A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose.

Cobleigh MA, Buonocore L, Uprichard SL, Rose JK, Robek MD.

J Virol. 2010 Aug;84(15):7513-22. doi: 10.1128/JVI.00200-10. Epub 2010 May 26.


Lambda and alpha interferons inhibit hepatitis B virus replication through a common molecular mechanism but with different in vivo activities.

Pagliaccetti NE, Chu EN, Bolen CR, Kleinstein SH, Robek MD.

Virology. 2010 Jun 5;401(2):197-206. doi: 10.1016/j.virol.2010.02.022. Epub 2010 Mar 29.


Inhibition of type III interferon activity by orthopoxvirus immunomodulatory proteins.

Bandi P, Pagliaccetti NE, Robek MD.

J Interferon Cytokine Res. 2010 Mar;30(3):123-34. doi: 10.1089/jir.2009.0049.


Bortezomib inhibits hepatitis B virus replication in transgenic mice.

Bandi P, Garcia ML, Booth CJ, Chisari FV, Robek MD.

Antimicrob Agents Chemother. 2010 Feb;54(2):749-56. doi: 10.1128/AAC.01101-09. Epub 2009 Nov 30.


Overexpression of Toll-like receptor 2/4 on monocytes modulates the activities of CD4(+)CD25(+) regulatory T cells in chronic hepatitis B virus infection.

Zhang Y, Lian JQ, Huang CX, Wang JP, Wei X, Nan XP, Yu HT, Jiang LL, Wang XQ, Zhuang Y, Li XH, Li Y, Wang PZ, Robek MD, Bai XF.

Virology. 2010 Feb 5;397(1):34-42. doi: 10.1016/j.virol.2009.11.007. Epub 2009 Nov 27.


Hepatitis B virus replication and release are independent of core lysine ubiquitination.

Garcia ML, Byfield R, Robek MD.

J Virol. 2009 May;83(10):4923-33. doi: 10.1128/JVI.02644-08. Epub 2009 Feb 25.


Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication.

Pagliaccetti NE, Eduardo R, Kleinstein SH, Mu XJ, Bandi P, Robek MD.

J Biol Chem. 2008 Oct 31;283(44):30079-89. doi: 10.1074/jbc.M804296200. Epub 2008 Aug 29.


Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.

Ying C, Li Y, Leung CH, Robek MD, Cheng YC.

Proc Natl Acad Sci U S A. 2007 May 15;104(20):8526-31. Epub 2007 May 8.


Role of immunoproteasome catalytic subunits in the immune response to hepatitis B virus.

Robek MD, Garcia ML, Boyd BS, Chisari FV.

J Virol. 2007 Jan;81(2):483-91. Epub 2006 Nov 1.


Cytomegalovirus induces interferon-stimulated gene expression and is attenuated by interferon in the developing brain.

van den Pol AN, Robek MD, Ghosh PK, Ozduman K, Bandi P, Whim MD, Wollmann G.

J Virol. 2007 Jan;81(1):332-48. Epub 2006 Oct 25.


Toll-like receptor signaling inhibits hepatitis B virus replication in vivo.

Isogawa M, Robek MD, Furuichi Y, Chisari FV.

J Virol. 2005 Jun;79(11):7269-72.


Lambda interferon inhibits hepatitis B and C virus replication.

Robek MD, Boyd BS, Chisari FV.

J Virol. 2005 Mar;79(6):3851-4.


Signal transduction pathways that inhibit hepatitis B virus replication.

Robek MD, Boyd BS, Wieland SF, Chisari FV.

Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1743-7. Epub 2004 Feb 2.


Inhibition of hepatitis B virus replication by interferon requires proteasome activity.

Robek MD, Wieland SF, Chisari FV.

J Virol. 2002 Apr;76(7):3570-4.


Functional role of pX open reading frame II of human T-lymphotropic virus type 1 in maintenance of viral loads in vivo.

Bartoe JT, Albrecht B, Collins ND, Robek MD, Ratner L, Green PL, Lairmore MD.

J Virol. 2000 Feb;74(3):1094-100.


Characterization and mutational studies of equine infectious anemia virus dUTPase.

Shao H, Robek MD, Threadgill DS, Mankowski LS, Cameron CE, Fuller FJ, Payne SL.

Biochim Biophys Acta. 1997 May 23;1339(2):181-91.


Incorporation of uracil into viral DNA correlates with reduced replication of EIAV in macrophages.

Steagall WK, Robek MD, Perry ST, Fuller FJ, Payne SL.

Virology. 1995 Jul 10;210(2):302-13.

Supplemental Content

Loading ...
Support Center